The data are early but de-risk the FT836 program and validate the Sword & Shield platform in solid tumors without conditioning chemo, a key differentiator. However, with only 2 efficacy-evaluable patients showing activity, the stock may see a modest positive move on proof-of-concept but faces binary risk from future enrollment expansion and durability data. Monitor for next data update and potential partnership interest.
Price Chart
Executive Summary
Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid tumors, at ASCO 2026. In two heavily pre-treated KRASwt metastatic colorectal cancer patients, FT836 plus cetuximab without conditioning chemotherapy showed a 19% tumor reduction (Case 1) and a 52% liver lesion reduction (Case 2), with no DLTs, CRS, ICANS, or GvHD across nine patients. The data demonstrate first-in-human proof of trafficking and persistence in tumor tissue without lymphodepletion, but the sample is tiny (n=9 safety, n=5 efficacy-evaluable, n=2 with anti-tumor activity) and early-stage, limiting immediate stock-moving impact.
Key Facts
- FT836 is an off-the-shelf, iPSC-derived CAR T-cell targeting MICA/B with Sword & Shield technology to eliminate need for conditioning chemotherapy.
- Nine patients enrolled across two regimens (FT836 + cetuximab, n=6; FT836 + trastuzumab, n=3); no DLTs, CRS, ICANS, or GvHD observed.
- Five patients available for efficacy; two KRASwt mCRC patients with 7 prior lines each showed tumor reduction: 19% sum-of-diameters (Case 1) and 52% liver lesion reduction (Case 2).
- FT836 detected in peripheral blood (peak Day 4) and tumor tissue (Day 22 biopsy) without conditioning chemotherapy, with evidence of tumor immune microenvironment remodeling.
- Company plans to focus on CRC patient population based on these results.
- Market cap ~$331M; analyst consensus 61% bullish (11 Buy, 7 Hold).
Financial Impact
No financial data provided; early-stage clinical data with no revenue or guidance impact.
Risk Factors
- Extremely small sample size (n=2 efficacy-evaluable with anti-tumor activity); results may not replicate in larger cohorts.
- No conditioning chemotherapy may limit CAR T persistence in broader patient populations; durability data are immature.
- Company is pre-revenue with no approved products; cash runway and financing risk remain.
- Competitive landscape includes multiple off-the-shelf CAR T and bispecific approaches in solid tumors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304368 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Press Release | $2.57 $2.34 | ▼ −8.95% | ▼ −6.96% | $2.32 (−9.73%) |
Aug 13, 2026 7w ago | 8-K | $2.52 $2.31 | ▼ −8.33% | ▼ −6.59% | $2.32 (−7.94%) |
Aug 5, 2026 8w ago | Insider Cluster | $2.49 $2.42 | ▲ +2.81% | ▲ +3.41% | $2.32 (+6.83%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.97 $3.11 | ▼ −57.87% | ▼ −55.98% | $2.32 (−17.77%) |
Jun 4, 2026 17w ago | 8-K | $1.98 $2.99 | ▲ +51.01% | ▲ +49.15% | $2.32 (+17.17%) |
Jun 1, 2026 17w ago | Press Release | $2.74 $2.70 | ▼ −1.46% | ▼ −0.16% | $2.32 (−15.33%) |
May 13, 2026 20w ago | 8-K | $2.14 $1.97 | ▼ −7.94% | ▼ −7.33% | $2.32 (+8.41%) |
May 11, 2026 20w ago | Press Release | $2.18 $1.90 | ▼ −12.84% | ▼ −12.54% | $2.32 (+6.42%) |
Apr 24, 2026 23w ago | DEFA14A | $1.31 $2.15 | ▲ +64.12% | ▲ +59.17% | $2.32 (+77.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access